Aurobindo Pharma appears in U.S. records for cephalexin, the prescription cephalosporin antibiotic historically associated with Keflex. Aurobindo-linked U.S. records cover cephalexin capsules and separately identify 2026 powder-for-suspension labels with 125 mg/5 mL and 250 mg/5 mL when prepared. A label is a document about a specific product family; it is not a guarantee of current retail stock or a recommendation of one generic company over another.
This guide focuses on evidence about Aurobindo rather than repeating the generic cephalexin product overview. Its practical task is to identify capsule strengths plus suspension concentrations of 125 mg per 5 mL and 250 mg per 5 mL, interpret the company role and determine what a pharmacist can verify on an actual prescription. Use the U.S. manufacturer index when comparing several company names.
For any prescription, check the active ingredient, product form, strength or concentration, pharmacist-confirmed NDC and written directions. An online pill image or DailyMed update cannot confirm what a particular pharmacy dispenses today. Cephalexin remains prescription-only, and differences in packaging do not authorize changes to treatment.
Aurobindo-associated records cover capsule products and separately published U.S. powder-for-suspension labels. Verify each document’s packager and manufacturer role rather than treating a corporate name as proof that every cephalexin strength is currently sold.
For a medicine in hand, use the printed package and pharmacy receipt as the starting point; product listings describe a label family, while the dispensed NDC identifies the actual packaged item.
| Your next question | Relevant Core guide | What it covers |
|---|---|---|
| Verify generic category | Generic products | Understand approved forms |
| Compare other companies | Manufacturer index | Compare labeling roles |
| Identify capsules | Cephalexin capsules | Check strength and imprint |
| Review liquid products | Cephalexin suspension | See concentrations and preparation |
| Need pharmacy availability | Availability checks | Ask about the actual NDC |
The documented focus here is capsule strengths plus suspension concentrations of 125 mg per 5 mL and 250 mg per 5 mL. The dose a patient should receive is determined by the prescription and medical context, not by which strength appears first in a manufacturer catalog.
Aurobindo suspension listings from 2026 identify Aurobindo Pharma Limited and U.S. distribution information; the manufacturer and distributor may appear in distinct document fields. When the pharmacy offers a different dosage form, ask the dispensing pharmacist whether the order permits it. See forms and strengths for the broader product matrix.
Aurobindo’s oral-suspension labels identify 125 mg/5 mL and 250 mg/5 mL preparations and specify finished bottle volumes. These are concrete distinctions from its capsules, which use milligrams per individual solid unit. A strength listed for one form must not be copied into claims about the other.
DailyMed identifies label revisions, product codes and, where provided, application identifiers. FDA Orange Book information has a distinct role in checking approved products and therapeutic equivalence; a label publication date is not itself proof that a product newly launched or was delivered to retailers.
The 2026 suspension label lists specific package volumes, but those descriptions are not a promise that a particular store can dispense one today. Record the exact source and date if using company data for a prescription or product question.
The Aurobindo suspension DailyMed record associates the product with ANDA 213568 and lists 2026 U.S. marketing information. That evidence supports a discussion of documented current records, not an assurance that any given local retailer carries the preparation. The applicable formulation and package must still be verified through dispensing channels.
On an Aurobindo cephalexin package, the NDC identifies the specific listed drug or package presentation. The FDA emphasizes that the presence of an NDC is not proof of FDA approval. The Orange Book and drug labeling answer different questions from a wholesaler or retail inventory report.
Ask a pharmacist to compare the NDC on the dispensed package against the prescription’s ingredient, strength and dosage form. A listed NDC does not prove the pack is available at a particular pharmacy or that Aurobindo physically manufactured every repackaged unit.
Some Aurobindo-associated labels distinguish Aurobindo Pharma Limited from the U.S. distribution entity. Those roles describe a particular supply and labeling arrangement, not a promise about the company that appears on every repackaged retail bottle.
The source label, application record and NDC may answer different questions: who submitted an application, which company is named on labeling, and which package is listed. Use the details of the product actually dispensed rather than attributing all roles to a single entity.
Capsule appearance can vary with the specific Aurobindo-associated NDC, lot and any permitted repackaging. Color and imprint comparisons are useful identifiers only when tied to the package label, not when inferred from a generic search image.
Before taking a capsule whose appearance differs from a prior refill, read the printed strength and imprint to the pharmacist. The pharmacist can compare the actual dispensed record with current official product identification information.
Aurobindo-associated cephalexin suspension documentation includes 125 mg/5 mL and 250 mg/5 mL product contexts. These are concentrations after correct pharmacy preparation; the same milliliter amount contains different quantities of antibiotic in the two strengths.
Confirm the exact prepared concentration and bottle volume shown on the dispensed label. Caregivers must use the supplied measuring device and pharmacy directions, never carry over a previous bottle’s mL instructions to a different concentration.
When a pharmacy can dispense an eligible therapeutically equivalent cephalexin product from a different labeler, it should check the active ingredient, dose form, strength, relevant Orange Book therapeutic-equivalence information and applicable prescription or state restrictions. Aurobindo labeling alone cannot authorize substitution.
A manufacturer change may alter appearance or excipients, but it does not mean the antibiotic class has changed. A different active ingredient, concentration or route is a separate clinical and pharmacy decision.
The existence of an Aurobindo label does not show whether an online or neighborhood pharmacy stocks that company’s product. Asking for a specific manufacturer may affect sourcing or turnaround time even when generic cephalexin is otherwise available.
Request a quote for the authorized product, including form, quantity and any coverage limitations, then verify current stock directly. Use the cost guide instead of using a company name as a price estimate.
Because both capsule and suspension records exist, a request for “Aurobindo cephalexin” is not specific enough for an inventory or price check. Give the pharmacy the precise dose form, strength or concentration and quantity. An NDC lookup can then help identify the particular presentation rather than treating the company name as the product.
Products associated with Aurobindo carry the same core cephalexin antibiotic considerations: hypersensitivity history, important interactions, renal function where relevant and evaluation for serious antibiotic-associated diarrhea. A manufacturer-specific page does not override the prescribed clinical indication.
For dosing or serious symptoms, use the prescribing clinician and dispensing pharmacist. The patient’s actual package and instructions determine the selected form; a company page is not a patient-specific dosing reference.
Confirm the cephalexin active ingredient, the particular Aurobindo label, package NDC, exact form or concentration, application context when relevant and pharmacy instructions. Separate current dispensing information from historical or public database entries.
For Aurobindo suspension, the prepared concentration (125 mg/5 mL or 250 mg/5 mL), intended bottle quantity and distributor/manufacturer identification must be read from the relevant label and the pharmacy order. The presence of a 2026 record does not demonstrate current local pharmacy stock.
Yes. DailyMed includes a cephalexin label associated with Aurobindo Pharma. Verify the particular form and the latest relevant record.
This page discusses capsule strengths plus suspension concentrations of 125 mg per 5 mL and 250 mg per 5 mL. A product record does not establish that every pharmacy carries each presentation.
Not necessarily. Labeler, distributor, packager, application holder and physical manufacturing roles can differ; consult the specific labeling statements.
No public label proves real-time retail stock. A pharmacy must confirm whether it can supply a particular product.
An eligible therapeutically equivalent generic may be dispensable under state law and prescription instructions. Ask the pharmacist to verify the specific substitution.
No. FDA states that assignment of an NDC alone does not indicate approval; check applicable approval records separately.
There is no reliable universal price ranking. Pharmacy, product, quantity, insurance and cash-discount terms change the final amount.
Yes. Regardless of manufacturer, cephalexin remains a prescription antibiotic in the United States.